National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

canertinib dihydrochloride
The hydrochloride salt of an orally bio-available quinazoline with potential antineoplastic and radiosensitizing activities. Canertinib binds to the intracellular domains of epidermal growth factor receptor tyrosine kinases (ErbB family), irreversibly inhibiting their signal transduction functions and resulting in tumor cell apoptosis and suppression of tumor cell proliferation. This agent also acts as a radiosensitizing agent and displays synergistic activity with other chemotherapeutic agents. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Synonym:CI-1033/PD183805
Code names:CI-1033
PD183805
Chemical structure names:
  • N-[-4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-2-propenamide
  • N-[-4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-2-propenamide Dihydrochloride



Previous:Camptogen, Camptosar, canarypox-hIL-12 melanoma vaccine, Cancidas, candesartan cilexetil
Next:cannabis-based oromucosal spray GW-1000-02, Canvaxin, capecitabine, Capoten, captopril

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov